DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your ...
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance ...
Humacyte announces publication of results on ATEV
Humacyte (HUMA) announced the publication of clinical results evaluating the efficacy and safety of the acellular tissue engineered vessel, ...
Endovascular Today14d
Humacyte’s ATEV Results Presented From V007 Phase 3 AV Access Trial
Humacyte, Inc. recently announced the presentation of results from the V007 phase 3 clinical trial of the company’s acel ...
Seeking Alpha28d
Revisiting Humacyte
Backing up a bit, Humacyte filed a BLA in December 2023 after its ATEV demonstrated superiority over a synthetic graft benchmark in a single-arm, open-label, unblinded Phase 2/3 trial (V005).
Yahoo Finance1d
Humacyte, Inc. (HUMA)
Management will host a webcast and conference call at 8:30 a.m. ET to discuss recent corporate updates from its acellular tissue engineered vessel (ATEV) programs. Title:Humacyt – ATEV ...
Morningstar7d
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance compared to current synthetic graft treatment benchmarks ...
Yahoo Finance7d
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
The publication “Bioengineered Human Arteries for the Repair of Vascular Injuries” describes two clinical studies in which the ATEV demonstrated benefits in terms of patency (blood flow), limb ...
Stockhouse7d
Humacyte Clinical Results Highlighting Benefit of the ATEV(TM) in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance compared to current synthetic graft treatment benchmarks – – ...